These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9407452)

  • 41. Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.
    Saito T; Iwano M; Matsumoto K; Mitarai T; Yokoyama H; Yorioka N; Nishi S; Yoshimura A; Sato H; Ogahara S; Sasatomi Y; Kataoka Y; Ueda S; Koyama A; Maruyama S; Nangaku M; Imai E; Matsuo S; Tomino Y;
    Clin Exp Nephrol; 2017 Dec; 21(6):961-970. PubMed ID: 27783276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy.
    Chen CH; Shu KH; Wen MC; Chen KJ; Cheng CH; Lian JD; Wu MJ; Yu TM; Tsai FJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3166-73. PubMed ID: 18495745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin.
    Gupta K; Iskandar SS; Daeihagh P; Ratliff HL; Bleyer AJ
    Nephrol Dial Transplant; 2008 May; 23(5):1595-9. PubMed ID: 18065791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Shortening of life expectancy in patients with membranous nephropathy--based on 20 years follow up study].
    Ogi M; Kida H; Yoshimura M; Saito Y; Kibe Y; Sugioka G; Ikeda K; Asamoto T; Yokoyama H; Tomosugi N
    Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1147-53. PubMed ID: 8264105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A clinicopathological analysis of non-haematological malignancy in nephrotic syndrome].
    Ye WL; Li H; Sun Y; Li XM; Li XW
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):897-900. PubMed ID: 19080228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteinuric glomerular disease in adults: cumulative life tables over twenty years.
    Blainey JD; Brewer DB; Hardwicke J
    Q J Med; 1986 Jun; 59(230):557-67. PubMed ID: 3749449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nephrotic syndrome in the elderly--clinicopathological study.
    Ozono Y; Harada T; Yamaguchi K; Taura K; Hara K; Taguchi T
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):44-50. PubMed ID: 8107308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nephrotic syndrome due to membranous nephropathy associated with renal cell carcinoma.
    Nishibara G; Sukemi T; Ikeda Y; Tomiyoshi Y
    Clin Nephrol; 1996 Jun; 45(6):424. PubMed ID: 8793244
    [No Abstract]   [Full Text] [Related]  

  • 49. Nephrotic syndrome caused by membranous nephropathy: response to a short course of cyclophosphamide alternating with prednisolone.
    Fujimoto S; Hara S; Sato Y; Yamada K; Hisanaga S; Eto T
    Intern Med; 2004 Jan; 43(1):30-4. PubMed ID: 14964576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Membranous glomerulonephritis and the nephrotic syndrome in a patient with Landry-Guillain-Barré-Strohl syndrome.
    Nicholson GD; Prussia PR; Sirarajan S; Evelyn SV
    West Indian Med J; 1989 Mar; 38(1):51-3. PubMed ID: 2728436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idiopathic membranous nephropathy: definition and relevance of a partial remission.
    Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC;
    Kidney Int; 2004 Sep; 66(3):1199-205. PubMed ID: 15327418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prognosis of chronic renal failure in patients with membranous nephropathy].
    Razukeviciene L; Kuzminskis V; Bumblyte IA; Laurinavicius A
    Medicina (Kaunas); 2003; 39 Suppl 1():9-15. PubMed ID: 12761414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Membranous nephropathy].
    Yokoyama H; Yoshimoto K; Wada T
    Nihon Rinsho; 2004 Oct; 62(10):1856-60. PubMed ID: 15500130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Membranous allograft nephropathy. Remission of nephrotic syndrome with pulsed methylprednisolone and high-dose alternate-day steroids.
    Johnston PA; Goode NP; Aparicio SR; Davison AM
    Transplantation; 1993 Jan; 55(1):214-6. PubMed ID: 8420053
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic strategy of nephrotic syndrome in patients over eighty.
    Noiri E; Okuda T; Takano T; Kurokawa K
    Nihon Jinzo Gakkai Shi; 1994 Aug; 36(8):902-6. PubMed ID: 7933665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.
    Thompson A; Cattran DC; Blank M; Nachman PH
    J Am Soc Nephrol; 2015 Dec; 26(12):2930-7. PubMed ID: 26078365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic modeling of clinical outcomes: an illustration with data from patients with membranous nephropathy.
    Sheehe PR
    Epidemiology; 1991 Sep; 2(5):339-47. PubMed ID: 1742382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Initiation of renin-angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.
    Shimizu S; Niihata K; Nishiwaki H; Shibagaki Y; Yamamoto R; Nitta K; Tsukamoto T; Uchida S; Takeda A; Okada H; Narita I; Isaka Y; Kurita N;
    Clin Exp Nephrol; 2023 May; 27(5):480-489. PubMed ID: 36840902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics and outcome of membranous nephropathy in older patients.
    O'Callaghan CA; Hicks J; Doll H; Sacks SH; Cameron JS
    Int Urol Nephrol; 2002; 33(1):157-65. PubMed ID: 12090324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete remission of primary membranous nephropathy following hepatitis E infection.
    Takanohashi S; Sugiura T; Koyano A; Ueno T; Rachi H; Shiratori K; Shimasaki M; Igarashi H; Kitayama Y; Togawa A
    CEN Case Rep; 2023 Nov; 12(4):384-389. PubMed ID: 36864232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.